Joint Pain Injections Market - Forecasts from 2023 to 2028

The Joint pain injections market is expected to grow at a CAGR of 6% to reach a market size of US$8.623 billion by 2028.

Overview

The Joint pain injections market is projected to grow steadily during the forecast period. Joint pain injections, also referred to as intra-articular injections, are minimally invasive procedures where medication is injected directly into a joint to relieve pain and inflammation. These injections are commonly used for the treatment of various joint conditions, such as osteoarthritis, arthritis, rheumatoid arthritis, and some other inflammatory conditions affecting the joints. The minimally invasive nature of these injections makes them a favorable option for chronic pain management in the older population.

Market Drivers:

Obesity and a sedentary lifestyle

Around the world, 650 million adults are currently obese and by 2025, the WHO predicts that 167 million adults and children will become less healthy owing to obesity. Obesity is a risk factor for joint diseases as excessive weight places additional strain on the joints and increases the likelihood of joint dysfunction. Even in younger age groups, the prevalence of joint illnesses is rising due to the rising obesity rates around the world. Further, inactivity and sedentary behaviour are common features of contemporary living that can cause the muscles that support the joints to become weaker and increase the risk of developing joint illnesses.

Rising geriatric population

According to the World Population Prospects 2022 report from the United Nations, the world's population will increase to about 8.5 billion in 2030 and reach 9.7 billion by 2050.. The most prevalent type of arthritis, osteoarthritis, is characterized by the deterioration of joint cartilage, which causes pain, stiffness, and decreased mobility in the affected joints. The rising geriatric population translates to a higher prevalence of joint conditions that require interventions like joint pain injections.

Market Restraints:

High cost and limited insurance coverage

Injections for joint discomfort can be expensive, especially if several injections are needed over time. The type of injection, the medicine, and the healthcare practitioner can all affect the price. The price of injections may be a barrier to access for those with insufficient insurance or inadequate financial resources. Further, the cost of joint pain injections may not be entirely covered by insurance depending on the type of injection and the individual insurance coverage. Higher out-of-pocket costs for those seeking certain therapies may arise from this.

Availability of alternatives

There are several alternatives to joint pain injections that can be taken into consideration. These options comprise physical therapy that emphasizes exercises, stretches, and methods to strengthen muscles, increase joint mobility, and lessen discomfort. Additionally, oral medications, including paracetamol, analgesics, and nonsteroidal anti-inflammatory drugs (NSAIDs), might be recommended to treat joint pain and inflammation. These drugs frequently work in conjunction with other therapies to relieve mild to severe joint pain. Further, braces, splints, and canes are assistive devices that offer external support, and they can be especially beneficial for people who suffer from joint instability or osteoarthritis.

Vendor analysis

Joint pain injections are provided by several pharmaceutical and medical equipment firms. A few examples of well-known businesses that produce joint pain injections include:

• Sanofi Genzyme is a Sanofi company that specializes in medical care. They provide knee osteoarthritis patients with hyaluronic acid-based joint pain injections. For example, Synvisc-One is approved for the treatment of knee osteoarthritis.
• Johnson & Johnson is a global manufacturer of pharmaceuticals and medical equipment. Their subsidiary, Janssen Pharmaceuticals, sells hyaluronic acid-based joint pain injections for osteoarthritis of the knee, such as MONOVISC and ORTHOVISC.
• Zimmer Biomet is a manufacturer of medical equipment with a focus on musculoskeletal care. They offer hyaluronic acid injections for osteoarthritis of the knee, such as Gel-One, to treat joint pain.
• Bioventus is a multinational manufacturer of medical devices with a focus on ortho-biologic solutions. Their offerings include joint pain injections that target knee osteoarthritis, such as DUROLANE and GELSYN-3.

HA injections have gained a significant market share.

By type, hyaluronic acid injections have gained a significant market share owing to the rising prevalence of osteoarthritis. The injections are intended to treat osteoarthritis-related pain and inflammation while increasing joint mobility. To treat joint discomfort, a number of companies have created hyaluronic acid injectable solutions. For instance, the hyaluronic acid injectable Euflexxa, made by Ferring Pharmaceuticals, is recognized for treating knee osteoarthritis. In those who are affected, it tries to lessen discomfort and increase movement.

Joint pain injections for knees

Based on joint type, the knees often require joint pain injections. Knee discomfort is a common complaint, particularly in elderly people and people who have diseases like osteoarthritis. The knee joint experiences a lot of stress and movement, which makes it more prone to deterioration. Hence, due to the high prevalence of knee pain, the share of joint pain injections for this market segment is anticipated to be the largest leading to product launches by companies. For instance, in August 2021, Seikagaku Corporation introduced HyLink for the treatment of knee osteoarthritis in Taiwan.

Regional Insights:

North America holds one of the significant market share.

North America holds a large market share owing to the rise in the number of chronic diseases, including osteoarthritis and rheumatoid arthritis. According to the American Autoimmune Related Diseases Association Inc., more than 50 million Americans are affected by autoimmune diseases. Further, by 2030, there will be 72 million instances of diagnosed arthritis cases in the United States, according to the Center for Disease Control and Prevention. This is expected to increase the demand for joint pain injections in the region. Further, major pharmaceutical companies based in the U.S. are involved in the production of joint pain injections.

Steady growth is anticipated for Europe.

Growth in the European market is attributed to a well-established pharmaceutical sector and constant developments in countries like Germany, France, and Switzerland. Germany is renowned for having a robust pharmaceutical sector and an advanced healthcare system. Joint pain injections are among the many medicinal items that are produced by German pharmaceutical businesses.

Asia Pacific will expand at one of the fastest CAGR.

Asia has a sizable market for joint pain management due to its huge and aging population. The pharmaceutical industries of nations like India, China, South Korea, and Singapore have the potential to create a variety of drugs, including injections for joint pain. Apart from manufacturing hubs, Asia is also emerging as a pharmaceutical R&D hub, increasing investments in the development of innovative therapies, including joint pain.

Segmentation:

BY PRODUCT

• Corticosteroid Injections
• Hyaluronic Acid Injections
• Platelet Rich Plasma Injections
• Others

BY JOINT TYPE

• Knee
• Hip
• Hand & Wrist
• Others

BY DISTRIBUTION CHANNEL

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

BY GEOGRAPHY

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• The Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others